OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on April 14, 2010. The report discloses compensation matters approved by the Compensation Committee of the Board of Directors during a meeting held on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is the approval of new stock option grants and annual base salaries for named executive officers, effective March 1, 2010.
- Stock Option Grants:
- Phillip Frost, M.D. (CEO & Chairman): 450,000 shares
- Jane H. Hsiao (Vice Chairman & CTO): 450,000 shares
- Steven D. Rubin (EVP - Administration): 265,000 shares
- Rao Uppaluri (SVP & CFO): 235,000 shares
- Annual Base Salaries (Effective March 1, 2010):
- Phillip Frost, M.D.: $460,000
- Jane H. Hsiao: $450,000
- Steven D. Rubin: $350,000
- Rao Uppaluri: $310,000
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the standard disclosure of executive compensation.
Investor Verification Checklist
- Verify the total number of shares authorized under the company's stock option plan to assess dilution impact.
- Confirm the exercise price and vesting schedule for the newly granted options, as these details are not included in this summary.
- Review the company's most recent 10-K or 10-Q for context on cash burn and liquidity relative to the increased fixed salary obligations.